{"entity":{"id":"acns0332","kind":"trial","name":"COG ACNS0332","aka":["ACNS0332"],"tldr":"ACNS0332 found that giving carboplatin alongside radiotherapy improved survival for children with the most aggressive group 3 medulloblastomas, while isotretinoin, tested in the same trial, did nothing and was dropped.","summary":"ACNS0332 randomised children and young adults with high-risk medulloblastoma (metastatic, incompletely resected or with anaplasia) to 36 Gy craniospinal radiotherapy plus weekly vincristine with or without daily carboplatin as a radiosensitiser, followed by maintenance chemotherapy with or without isotretinoin. The isotretinoin randomisation closed early for futility.\n\nCarboplatin during radiotherapy did not improve event-free survival in the whole cohort, but in the molecularly defined group 3 subgroup it improved event-free and overall survival, a finding that came from the trial's tumour profiling. The result made carboplatin radiosensitisation a standard for group 3 high-risk disease and was one of the first paediatric brain tumour trials to show benefit in a molecular subgroup.","status":"mixed","asOf":"2026-09-17","links":[{"label":"ClinicalTrials.gov NCT00392327","url":"https://clinicaltrials.gov/study/NCT00392327"}],"tags":["subtype-trials"],"related":[],"cancers":["medulloblastoma-group-3-4","medulloblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":["carboplatin","vincristine","cisplatin","cyclophosphamide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["sarah-leary"],"bottlenecks":[],"keyPapers":["paper-acns0332-leary-jama-oncol-2021"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00392327","phase":"3","setting":"Newly diagnosed high-risk medulloblastoma in children aged 3 to 21: craniospinal radiotherapy with weekly vincristine, with or without daily carboplatin, and with or without isotretinoin maintenance","sponsor":"Children's Oncology Group","result":"Carboplatin radiosensitisation improved event-free and overall survival in group 3 high-risk medulloblastoma; isotretinoin maintenance was stopped for futility.","yearReported":2021,"enrolled":379,"outcomes":[]},"route":"/trials/acns0332/","neighbours":{"cancer":[{"id":"medulloblastoma-group-3-4","kind":"cancer","name":"Group 3 and group 4 medulloblastoma (non-WNT/non-SHH)","route":"/cancers/medulloblastoma-group-3-4/"},{"id":"medulloblastoma","kind":"cancer","name":"Medulloblastoma","route":"/cancers/medulloblastoma/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"vincristine","kind":"drug","name":"Vincristine","route":"/drugs/vincristine/"}],"person":[{"id":"sarah-leary","kind":"person","name":"Sarah E. S. Leary","route":"/people/sarah-leary/"}],"paper":[{"id":"paper-acns0332-leary-jama-oncol-2021","kind":"paper","name":"ACNS0332: carboplatin during radiotherapy and isotretinoin maintenance in high-risk medulloblastoma","route":"/key-papers/paper-acns0332-leary-jama-oncol-2021/"}]}}